GRACE SCIENCE FOUNDATION: Form 990, tax year 2022

View the entire original 990 at ProPublica ↗

Organization
GRACE SCIENCE FOUNDATION (EIN 46-5727883)
Tax period
2022-01-01 to 2022-12-31
Filed
2023-11-16
IRS object ID
202313219349300501
Schema version
2022v5.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2023-11-16T23:02:16-06:00ReturnTs
Tax Period End2022-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1WITHUMSMITHBROWNPCBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1601 CALIFORNIA STREET SUITE 1800AddressLine1Txt
CitySAN FRANCISCOCityNm
State AbbreviationCAStateAbbreviationCd
ZIP94108ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2022-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN465727883EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1Grace Science FoundationBusinessNameLine1Txt
FieldValueIRS element (for citing)
In Care Of% GRACE SCIENCE FOUNDATIONInCareOfNm
Business Name ControlGRACBusinessNameControlTxt
Phone6507464591PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1873 SANTA CRUZ AVENUE SUITE 200AddressLine1Txt
CityMENLO PARKCityNm
State AbbreviationCAStateAbbreviationCd
ZIP94025ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonMATTHEW R WILSEYPersonNm
Person TitlePRESIDENTPersonTitleTxt
Phone6507464591PhoneNum
Signature2023-11-16SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

FieldValueIRS element (for citing)
Person FirstMATTHEW RPersonFirstNm
Person LastWILSEYPersonLastNm
FieldValueIRS element (for citing)
SSNXXX-XX-XXXXSSN

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonRebecca StidhamPreparerPersonNm
PTINP01406582PTIN
Phone4154343744PhoneNum

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

FieldValueIRS element (for citing)
Trusted Customer2TrustedCustomerCd
FieldValueIRS element (for citing)
Tax2022TaxYr
Build TS2023-04-26 12:10:37ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Address ChangeYes (X)AddressChangeInd
Principal OfficerMATTHEW R WILSEYPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1873 SANTA CRUZ AVENUE SUITE 200AddressLine1Txt
CityMENLO PARKCityNm
State AbbreviationCAStateAbbreviationCd
ZIP94025ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$1,236,228GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website Addresswww.gracescience.orgWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2014FormationYr
Legal Domicile StateCALegalDomicileStateCd
Activity Or MissionSEE PART III LINE 1ActivityOrMissionDesc
Voting Members Governing Body7VotingMembersGoverningBodyCnt
Voting Members Independent7VotingMembersIndependentCnt
Total Employee0TotalEmployeeCnt
Total Volunteers0TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$1,325,647PYContributionsGrantsAmt
CY Contributions Grants$1,206,450CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$1,466PYInvestmentIncomeAmt
CY Investment Income$29,778CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$1,327,113PYTotalRevenueAmt
CY Total Revenue$1,236,228CYTotalRevenueAmt
PY Grants And Similar Paid$885,550PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$967,948CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$0PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$0CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$0CYTotalFundraisingExpenseAmt
PY Other Expenses$227,582PYOtherExpensesAmt
CY Other Expenses$250,534CYOtherExpensesAmt
PY Total Expenses$1,113,132PYTotalExpensesAmt
CY Total Expenses$1,218,482CYTotalExpensesAmt
PY Revenues Less Expenses$213,981PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$17,746CYRevenuesLessExpensesAmt
Total Assets BOY$3,128,030TotalAssetsBOYAmt
Total Assets EOY$3,183,591TotalAssetsEOYAmt
Total Liabilities BOY$29,929TotalLiabilitiesBOYAmt
Total Liabilities EOY$51,224TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$3,098,101NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$3,132,367NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESESARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTNADING AND TREATMENT OF THIS CONDITION, FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$298,348ExpenseAmt
Grant$298,348GrantAmt
DescTHE Charles River Laboratories Team has imported and is maintaining a colony of Ngly1 knockout rats for use in evaluating therapies to treat NGLY1 Deficiency. This knockout model has been a key foundation to test adeno-associated virus (AAV)-mediated gene delivery for rescue of disease-associated phenotypes and has supported an investigational new drug (IND) application to the FDA for an NGLY1 Deficiency gene therapy clinical study. Team has also conducted a study to monitor clinical phenotypes and collect biological samples in homozygous mutant and heterozygous (carrier) NGLY1 knockout rats across the lifespan from birth to eighteen months of age.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$133,374ExpenseAmt
Grant$133,374GrantAmt
DescThe Scripps Research Institute (Bollong Lab) Team is testing the ability of small molecule modulators of the transcriptional regulators NRF1 (NFE2L1) and NRF2 (NFE2L2) for the rescue of phenotypic changes associated with NGLY1 Deficiency. The team has identified NRF1 modulating compounds that protect NGLY1 knockout cells from proteasomal stress and has been characterizing their activity. In addition, a potent and selective brain penetrant NRF2 modulating compound has been identified and is being characterized and formulated for in vivo testing. These compounds establish a proof of concept for NGLY1 Deficiency therapy development based on NRF1/2 modulation.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$132,178ExpenseAmt
Grant$132,178GrantAmt
DescThe T. David Gladstone Institute (Finbeiner Lab) Team has imported and is analyzing cellular phenotypes in a neuronal model of NGLY1 Deficiency to define disease mechanisms for the design and testing of candidate therapies. The team has been using robotic microscopy to investigate phenotypic differences in an NGLY1 mutant human neural cell line following differentiation from neural precursor cells to mature neurons. The team is using genetically encoded biosensors to monitor cell viability, mitochondrial shape and dynamics, proteasomal activity, autophagy flux, protein aggregation and NRF1-dependent transcriptional activity. The goal is to identify cellular changes that can be used to assess or screen for candidate drugs that can correct cellular changes caused by NGLY1 Deficiency.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (16 entries)

ExpenseExpenseAmtGrantGrantAmtDescDesc
$114,390$114,390The University of Texas SW Medical Center (Yan Lab
$55,000$55,000The New York Stem Cell Foundation
$49,110$49,110Boston's Children's Hospital (Yu Lab)
$48,500$48,500Albert Einstein's College of Medicine-Kaushik Lab
$37,934$37,934Hilltop Lab Animals, Inc.
$25,367$25,367Baylor College of Medicine (Jafar-Nejad Lab)
$23,872$23,872Purdue University
$16,998$16,998University of Houston
$12,500$12,500The Regents of the University of California
$8,552$8,552Qiagen, LLC
$5,098$5,098Transnetyx
$2,300$2,300Genetic Alliance
$1,978$1,978BPS Bioscience
$1,360$1,360Reveal Bioscience
$1,000$1,000The Jackson Laboratory
$89$89Luna PBC, Inc.
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$404,048TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant$404,048TotalOtherProgSrvcGrantAmt
Total Program Service Expenses$967,948TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesfalseLobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtfalseCollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Donor Rstr Or Quasi EndowmentsfalseDonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentfalseReportLandBuildingEquipmentInd
Report Investments Other SecfalseReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnotefalseIncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtfalseConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficefalseForeignOfficeInd
Foreign ActivitiesfalseForeignActivitiesInd
More Than5000 K To OrgfalseMoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingfalseProfessionalFundraisingInd
Fundraising ActivitiesfalseFundraisingActivitiesInd
Gaming ActivitiesfalseGamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsfalseGrantsToIndividualsInd
Schedule J RequiredfalseScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With35 Ctrl EntfalseBusinessRlnWith35CtrlEntInd
Deductible Non Cash ContrifalseDeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityfalseDisregardedEntityInd
Related EntityfalseRelatedEntityInd
Related Organization Ctrl EntfalseRelatedOrganizationCtrlEntInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document4IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee0EmployeeCnt
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountfalseForeignFinancialAccountInd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsfalseQuidProQuoContributionsInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht PymtfalseSubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst IncfalseSubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members7GoverningBodyVotingMembersCnt
Independent Voting Member7IndependentVotingMemberCnt
Family Or Business RlnYes (true)FamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersfalseMembersOrStockholdersInd
Election Of Board MembersYes (true)ElectionOfBoardMembersInd
Decisions Subject To ApprovafalseDecisionsSubjectToApprovaInd
Minutes Of Governing BodyfalseMinutesOfGoverningBodyInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersfalseLocalChaptersInd
Form990 Provided To Gvrn BodyfalseForm990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnfalseAnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcfalseRegularMonitoringEnfrcInd
Whistleblower PolicyfalseWhistleblowerPolicyInd
Document Retention PolicyfalseDocumentRetentionPolicyInd
Compensation Process CEOfalseCompensationProcessCEOInd
Compensation Process OtherfalseCompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
Other WebsiteYes (X)OtherWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonGRACE SCIENCE FOUNDATIONPersonNm
Phone6507464591PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1873 SANTA CRUZ AVENUE SUITE 200AddressLine1Txt
CityMENLO PARKCityNm
State AbbreviationCAStateAbbreviationCd
ZIP94025ZIPCd
FieldValueIRS element (for citing)
Info In Schedule O Part VIIYes (X)InfoInScheduleOPartVIIInd
No Listed Persons CompensatedYes (X)NoListedPersonsCompensatedInd

Form990 Part VII Section A Form990PartVIISectionAGrp (7 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmt
Matthew Wilsey
President0.00.0Yes (X)Yes (X)$0$0$0
Egon Durban
Chief Financial Officer0.00.0Yes (X)Yes (X)$0$0$0
KEN DRAZAN
Secretary0.00.0Yes (X)Yes (X)$0$0$0
Pete Briger
Director0.00.0Yes (X)$0$0$0
Chelsea Clinton
Director0.00.0Yes (X)$0$0$0
J Taylor Crandall
Director0.00.0Yes (X)$0$0$0
Elle Stephens
Director0.00.0Yes (X)$0$0$0
FieldValueIRS element (for citing)
Total Reportable Comp From Org$0TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$0TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K0IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedfalseFormerOfcrEmployeesListedInd
Total Comp Greater Than150 KfalseTotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp

Contractor Name ContractorName

FieldValueIRS element (for citing)
PersonKEVIN LEEPersonNm

Contractor Address ContractorAddress

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CENTRAL PARK WEST 7DAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10025ZIPCd
FieldValueIRS element (for citing)
ServicesCONSULTINGServicesDesc
Compensation$101,332CompensationAmt
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K1CntrctRcvdGreaterThan100KCnt
All Other Contributions$1,206,450AllOtherContributionsAmt
Total Contributions$1,206,450TotalContributionsAmt
Total Program Service Revenue$0TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$29,778TotalRevenueColumnAmt
Exclusion$29,778ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Rental Income Or Loss RentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Real$0RealAmt
Personal$0PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$0FundraisingGrossIncomeAmt
Fundraising Direct Expenses$0FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
FieldValueIRS element (for citing)
Gaming Gross Income$0GamingGrossIncomeAmt
Gaming Direct Expenses$0GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
FieldValueIRS element (for citing)
Gross Sales Of Inventory$0GrossSalesOfInventoryAmt
Cost Of Goods Sold$0CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

FieldValueIRS element (for citing)
Total Revenue Column$0TotalRevenueColumnAmt
FieldValueIRS element (for citing)
Other Revenue Total$0OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,236,228TotalRevenueColumnAmt
Exclusion$29,778ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$967,948TotalAmt
Program Services$967,948ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Benefits To Members BenefitsToMembersGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Comp Disqual Persons CompDisqualPersonsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Services Management FeesForServicesManagementGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$11,298TotalAmt
Management And General$11,298ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$12,600TotalAmt
Management And General$12,600ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$139,219TotalAmt
Management And General$139,219ManagementAndGeneralAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$8,041TotalAmt
Management And General$8,041ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$2,395TotalAmt
Management And General$2,395ManagementAndGeneralAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$1,597TotalAmt
Management And General$1,597ManagementAndGeneralAmt

Royalties RoyaltiesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$61,828TotalAmt
Management And General$61,828ManagementAndGeneralAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$791TotalAmt
Management And General$791ManagementAndGeneralAmt

Interest InterestGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Payments To Affiliates PaymentsToAffiliatesGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$0TotalAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$970TotalAmt
Management And General$970ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtManagement And GeneralManagementAndGeneralAmt
SHIPPING FEES$6,891$6,891
REIMBURSABLE EXPENSES$4,904$4,904

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$1,218,482TotalAmt
Program Services$967,948ProgramServicesAmt
Management And General$250,534ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$381,790BOYAmt
EOY$186,218EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$2,745,587BOYAmt
EOY$2,996,735EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$653BOYAmt
EOY$638EOYAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Intangible Assets IntangibleAssetsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$3,128,030BOYAmt
EOY$3,183,591EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$29,929BOYAmt
EOY$51,224EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$29,929BOYAmt
EOY$51,224EOYAmt
FieldValueIRS element (for citing)
Org Does Not Follow FASB117Yes (X)OrgDoesNotFollowFASB117Ind

Cap Stk Tr Prin Current Funds CapStkTrPrinCurrentFundsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Pd In Cap Srpls Land Bldg Eqp Fund PdInCapSrplsLandBldgEqpFundGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Rtn Earn Endowment Incm Oth Fnds RtnEarnEndowmentIncmOthFndsGrp

FieldValueIRS element (for citing)
BOY$0BOYAmt
EOY$0EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$3,098,101BOYAmt
EOY$3,132,367EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$3,128,030BOYAmt
EOY$3,183,591EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss$17,746ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$16,520NetUnrlzdGainsLossesInvstAmt
Method Of Accounting CashYes (X)MethodOfAccountingCashInd
Accountant Compile Or ReviewfalseAccountantCompileOrReviewInd
FS AuditedfalseFSAuditedInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,157,365CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,522,789CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,447,474CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,325,647CurrentTaxYearMinus1YearAmt
Current Tax Year$1,206,450CurrentTaxYearAmt
Total$6,659,725TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,157,365CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$1,522,789CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,447,474CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,325,647CurrentTaxYearMinus1YearAmt
Current Tax Year$1,206,450CurrentTaxYearAmt
Total$6,659,725TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$2,407,154SubstantialContributorsTotAmt
Public Support Total170$4,252,571PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus3 Years$20,581CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$6,706CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$1,466CurrentTaxYearMinus1YearAmt
Current Tax Year$29,778CurrentTaxYearAmt
Total$58,531TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Total$0TotalAmt
FieldValueIRS element (for citing)
Total Support$6,718,256TotalSupportAmt
Public Support CY1700.63299PublicSupportCY170Pct
Public Support PY1700.64835PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule I IRS990ScheduleI

Recipient Table RecipientTable (14 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdCash GrantCashGrantAmtPurpose Of GrantPurposeOfGrantTxtRecipient EINRecipientEIN
CHARLES RIVER LABORATORIES
251 BALLARDVALE STREETWILMINGTONMA01887$298,348NGLY1
CALIBR
11119 N TORREY PINESLA JOLLACA92037$133,374NGLY1 (BOLLONG LAB)
THE T DAVID GLADSTONE INSTITUTE
1650 OWENS STREETSAN FRANCISCOCA94158$132,178NGLY1 (FINKBEINER LAB)
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTE
5323 HARRY HINES BLVDDALLASTX75390$114,390NGLY1 (YAN LAB)
NEW YORK STEM CELL FOUNDATION INC
619 W 54TH STNEW YORKNY10019$55,000NGLY1202905531
BOSTON CHILDREN'S HOSPITAL
300 LONGWOOD AVENUEBOSTONMA02115$49,110NGLY1 (YU LAB)
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVENUEBRONXNY10461$48,500NGLY1 (KAUSHIK LAB)
HILLTOP LAB ANIMALS INC
131 HILLTOP DRSCOTTDALEPA15683$37,934NGLY1
BAYLOR COLLEGE OF MEDICINE
ONE BAYLOR PLAZA BCM 200HOUSTONTX77030$25,367NGLY1 (JAFAR-NEJAD LAB)741613278
PURDUE UNIVERSITY
610 PURDUE MALLWEST LAFAYETTEIN47907$23,872NGLY1
UNIVERSITY OF HOUSTON
4800 CALHOUN ROADHOUSTONTX77204$16,998NGLY1
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
1111 FRANKLIN STOAKLANDCA94607$12,500NGLY1
QIAGEN LLC
19300 GERMANTOWN ROADGERMANTOWNMD20874$8,552NGLY1
TRANSNETYX
8110 Cordova Rd Ste 119CORDOVATN38016$5,098NGLY1

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
Part I Description of Procedure for Monitoring Use of Funds* BEFORE FUNDING A PRINCIPAL INVESTIGATOR, THE FOUNDATION REQUIRES A DETAILED PROPOSAL WITH OBJECTIVES AND MILESTONES. * THE PROPOSALS ARE REVIEWED BY THE FOUNDATION AND SCIENTIFIC ADVISORY BOARD. * THE PROPOSALS ARE OFTEN REVISED SEVERAL TIMES TO GET THE CORRECT FIT. * Once funded, each principal investigator submits a written summary every quarter. * This update is two to three pages in length. * The reports discuss progress, highlight roadblocks and identify where they need help. *THE FOUNDATION STEPS-IN WHERE APPROPRIATE TO MAKE SURE OBJECTIVES AND MILESTONES ARE MET. * IN ADDITION TO QUARTERLY REPORTS, THE FOUNDATION HOLDS A MONTHLY CONFERENCE CALL WHERE TWO TO THREE PRINCIPAL INVESTIGATORS PRESENT THEIR LATEST WORK. * BEYOND THE ABOVE TWO INITIATIVES, THE FOUNDATION HOLDS ONE TO TWO IN-PERSON MEETINGS PER YEAR. * DR. KEVIN LEE (CHIEF SCIENTIFIC OFFICER), DR. SELINA DWIGHT (PROGRAM MANAGER), AND MATT WILSEY(PRESIDENT) CONTACT RESEARCHERS AND PRINCIPAL INVESTIGATORS ON A REGULAR BASIS VIA EMAIL, PHONE, OR ONE ON ONE MEETINGS. THE PRESIDENT ENSURES THAT EVERY DOLLAR IS USED TO SUPPORT THE GRACE SCIENCE FOUNDATION'S MISSION.
PART II:THE FOUNDATION REQUESTS AND OBTAINS TO THE BEST OF THEIR ABILITY THE FEIN'S FROM ORGANIZATIONS IT PROVIDES GRANT FUNDING.

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (14 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE UNIVERISTY OF TEXAS SOUTHWESTERN MEDICAL CENTER (YAN LAB) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival. suggest potential targets for candidate therapy development. EXPENSES $114,390. INCLUDING GRANTS OF $114,390. REVENUE $0.
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE NEW YORK STEM CELL FOUNDATION Team has developed and validated four additional patient-derived induced pluripotent stem cell (iPSC) lines to complement and expand human cell models of NGLY1 Deficiency. CRISPR-mediated genome editing was used to produce isogenic control lines to establish disease-specific characteristics. Team has further used these iPSC lines to generate human neuronal models of NGLY1 Deficiency and has characterized NGLY1-dependent neuronal phenotypes including changes in cellular architecture, mitochondrial function, intracellular aggregates, neuronal activity, and patterns of gene expression. Team has tested whether these pathologies can be reversed by restoring NGLY1 function or blocking oxidative stress-induced cell death. EXPENSES $55,000. INCLUDING GRANTS OF $55,000. REVENUE $0.
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE BOSTON CHILDREN'S HOSPITAL (YU LAB) Team is developing tools and resources to determine whether knockdown of the gene FBXO6 (F-box gene 6) can rescue phenotypic consequences associated with NGLY1 Deficiency. The team established a cellular assay system to test the ability of anti-sense oligonucleotides (ASOs) to knockdown FBXO6 and designed and tested a series of candidate ASOs. The team identified a series of ASOs that inhibit FBXO6 by >75% and initiated studies to assess their activity to block FBXO6 function in cells. These studies set the stage for subsequent research to test rescue of NGLY1-associated phenotypes in cellular and in vivo systems. EXPENSES $49,110. INCLUDING GRANTS OF $49,110. REVENUE $0.
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE ALBERT EINSTEIN COLLEGE OF MEDICINE (KAUSHIK LAB) Team is testing the hypothesis that defects in NGLY1 function leads to the impairment of cellular proteostasis pathways that recognize and clear misfolded and aggregated proteins and defective organelles. Using NGLY1 knockout rat and mouse tissues, NGLY1 mutant cell lines, and NGLY1 Deficiency patient fibroblasts, the team has observed significant impairment in macro- and chaperone mediated-autophagy and defects in lysosomal biogenesis. These results highlight the potential of drugs that target the autophagy-lysosome pathway to reverse cellular defects associated with NGLY1 Deficiency. The team has begun evaluating drug-like chemical modulators of the autophagy-lysosomal system for their ability to reduce cellular proteotoxicity in NGLY1 deficiency models. EXPENSES $48,500. INCLUDING GRANTS OF $48,500. REVENUE $0.
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE HILLTOP LAB ANIMALS, INC. Team has imported and established a colony of Ngly1 knockout mice for use in testing therapies to treat NGLY1 Deficiency. A breeding colony has been established, and mutant phenotypes have been characterized. This model system has been used to test drug candidates for their ability to rescue NGLY1 Deficiency-associated neurological symptoms and for genetic studies to test whether blocking other pathways (including FBXO6) has potential to treat NGLY1 Deficiency. EXPENSES $37,934. INCLUDING GRANTS OF $37,934. REVENUE $0.
FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICESTHE BAYLOR COLLEGE OF MEDICINE (JAFAR-NEJAD LAB) Team continues genetic and pharmacological studies to gain insights into pathways regulated by NGLY1 and potential targets for therapy development. This research has uncovered a link between NGLY1 and AMP-regulated kinase (AMPK) a critical cellular energy sensor. AMPK activity is reduced in animal models of NGLY1 Deficiency and in patient cell lines. Restoring AMPK levels or activity by genetic or pharmacological tools restores energy homeostasis in NGLY1 deficient cells and organisms. Team is researching the mechanisms and cellular contexts of AMPK regulation by NGLY1 and testing potential therapies to reverse AMPK-associated pathologies in NGLY1 Deficiency. EXPENSES $25,367. INCLUDING GRANTS OF $25,367. REVENUE $0.
FORM 990, PART VI, SECTION A, LINE 2:THE PRESIDENT OF THE FOUNDATION HAS IMMATERIAL OWNERSHIP INTEREST, IN THE IVNESTMENTS OF FORTRESS AND SILVERLAKE, WHICH ARE MANAGED BY TWO OF THE DIRECTORS.
FORM 990, PART VI, SECTION A, LINE 7A:THE PRESIDENT OF THE FOUNDATION HAS AUTHORITY TO ELECT ONE OR MORE MEMBERS OF THE GOVERNING BODY.
FORM 990, PART VI, SECTION A, LINE 8A:THE GOVERNING BODY OF THE FOUNDATION DID NOT MEET DURING THE YEAR.
FORM 990, PART VI, SECTION A, LINE 8B:THE FOUNDATION DOES NOT HAVE ANY COMMITTEES.
FORM 990, PART VI, SECTION B, LINE 11B:PRIOR TO FILING FORM 990, THE FOUNDATION'S PRESIDENT WILL REVIEW THE FORM.
FORM 990, PART VI, SECTION C, LINE 18:AVAILABLE UPON REQUEST.
FORM 990, PART VI, SECTION C, LINE 19:AVAILABLE UPON REQUEST.
FORM 990 PART IX LINE 11GDESCRIPTION:CONSULTING TOTAL FEES:139219

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.